Evidence map›Paper›PMID 30626825›Full record

ArticleInternal medicine (Tokyo, Japan)2019

Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout.

Akiko Katayama, Hirohide Yokokawa, Hiroshi Fukuda, Yoshiki Ono, Hiroshi Isonuma, Teruhiko Hisaoka, Toshio Naito

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Akiko KatayamaDepartment of General Medicine, Juntendo University School of Medicine, Japan.
Hirohide YokokawaDepartment of General Medicine, Juntendo University School of Medicine, Japan.
Hiroshi FukudaDepartment of General Medicine, Juntendo University School of Medicine, Japan.
Yoshiki OnoDepartment of Health Screening, Tokyo Health Service Association, Japan.
Hiroshi IsonumaDepartment of General Medicine, Juntendo University School of Medicine, Japan.
Teruhiko HisaokaDepartment of General Medicine, Juntendo University School of Medicine, Japan.
Toshio NaitoDepartment of General Medicine, Juntendo University School of Medicine, Japan.
Juntendo University · JPJapan Industrial Safety and Health Association · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective To assess the rate of successfully achieving treatment goals among Japanese men with hyperuricemia/gout and identify factors influencing the success rate. Methods This cross-sectional study, conducted from January to December 2012, examined the serum uric acid (SUA) levels and clinical characteristics of 2,103 men with hyperuricemia/gout selected from an initial population of 136,770 individuals who participated in a workplace health checkup. The success rates (defined as SUA ≤6.0 mg/dL) were calculated, and a multivariate analysis was used to identify factors associated with "therapeutic failure" to achieve target SUA levels. Results The rate of successfully achieving the target SUA level was 37.5%. The body mass index (BMI) was significantly associated with therapeutic failure [25.0≤ Category (C) 2<27.5, adjusted odds ratio (AOR) =1.35; 27.5≤C3<30.0, AOR=1.69; C4 ≥ 30.0, AOR=1.94; relative to C1<25.0]. A significant positive association was also observed between waist circumference (WC) and therapeutic failure (85≤C2<90, OR=1.29; 90≤C3<95, OR=1.41; 95≤C4, OR=2.28; relative to C1<85.0 cm). Those with higher BMI/WC measurements were significantly more likely to have higher SUA levels than those with lower such measurements. The ongoing intake of dyslipidemia medication was identified as a protective factor against therapeutic failure. Discussion Our findings suggest a possible association between obesity and therapeutic failure, underscoring the importance of maintaining lipid profiles as part of managing SUA levels. Better management of both obesity and dyslipidemia may prevent future cardiovascular disorders by ensuring healthier SUA levels.

Indexed as

AdultAgedAnthropometryBody Mass IndexCross-Sectional StudiesDrug MonitoringDyslipidemiasGoutGout SuppressantsHumansHyperuricemiaMaleMiddle AgedMultivariate AnalysisObesityRisk FactorsGout SuppressantsUric Acidachievement rateepidemiologylifestyle-related disorderobesitypreventionuric acid

Identifiers

PMID30626825
PMCPMC6543211
OpenAlexW2911029789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.